Search for a trial

A Phase 1/2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL) (TRANSCEND PEDALL)

Phase 1:To identify the recommended Phase 2 dose (RP2D) of JCAR017 in pediatric subjects withCD19+ r/r B-ALL.Phase 2:To evaluate the following efficacy endpoints of the JCAR017 RP2D identified in Phase 1, in the following three diseasecohorts:•…

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination with Obinutuzumab (GA101) in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin*s Lymphoma

Primary Objectives:• Determine the safety and tolerability of CC-122 administered in combination with obinutuzumab.• Determine the non-tolerated dose (NTD), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of CC-122 administered in…

Phase 1B/Phase 3 Multicenter Study of Avelumab (MSB0010718c) in Combination Regimens that Include an Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Primary objective:- To assess safety, efficacy, and potentially select the most active treatment regimen among 3 treatment arms to advance to the Phase 3 component of the study.Secondary objectives:- Ph1b: evaluate PK & assess immunogenicity…

Intracellular drug measurements to predict toxicity in high-dose methotrexate therapy in leukaemia and central nervous system lymphoma: a pilot study

A) To investigate the pharmacokinetics and determinants of MTX-PG accumulation in plasma and erythrocytes in adult CNS lymphoma and leukemia patients treated with HD-MTX;B) To investigate whether intracellular MTX levels are related to toxicity in…

A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U.

Primary objective:To evaluate the CR rate of MYC+ DLBCL and MYC+ BCL-U patients as assessed by end-of-treatment negative 18F-FDG PET-CT and BMSecundary objectives:- To evaluate the Disease Free Survival (DFS) at 2 years from time of complete…

Development of blood-based monitoring techniques in lymphatic malignancies

Development of blood-based monitoring techniques for treatment response evaluation and diagnostics in lymphoid neoplasms, including HL and NHL by using extracellular vesicle and cfDNA techniques for biomarker discovery, assay development and…

The pathogenesis of B-cell non-Hodgkin lymphoma after exposure to C. burnetii: a micro-array study to unravel the genetic pathway

To clarify the pathophysiological genetic pathway of the association between C. burnetii and NHL

Vitamin D status and peripheral neuropathy in multiple myeloma patients

The primary objective of this study is to determine the correlation between the 25-hydroxyvitamin D serum levels and PN in patients with multiple myeloma.

Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation. Transplant BRaVE NHL

This study has been transitioned to CTIS with ID 2023-510556-22-00 check the CTIS register for the current data. Lead in phase 1Primary objective:• To identify the feasibility and RDL (recommended dose level) of brentuximab vedotin in combination…

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations

This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 in subjects 18 years and older with RR DLBCL, including those with MYC Alterations.